Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4463-4465

  Prabhu, Rajesh M ^a   Piper, Kerryl E ^a   Baddour, Larry M ^a   Steckelberg, James M ^a   Wilson, Walter R ^a   Patel, Robin ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; ENDOCARDITIS, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; VANCOMYCIN RESISTANCE; VIRIDANS STREPTOCOCCI;

EID: 7244248668     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4463-4465.2004     Document Type: Article

References (28)

1. Bayer, A. S., and W. M. Scheid. 2000. Endocarditis and intravascular infections, p. 857-884. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Inc., New York, N.Y.
2. Bochud, P. Y., P. Eggiman, T. Calandra, G. Van Melle, L. Saghafi, and P. Francioli. 1994. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin. Infect. Dis. 18:25-31.
3. Bourgault, A. M., W. R. Wilson, and J. A. Washington. 1979. Antimicrobial susceptibilities of species of viridans streptococci. 3. Infect. Dis. 140:316-321.
4. Broun, E. R., J. L. Wheat, P. H. Kneebone, K. Sundblad, R. A. Hromas, and G. Tricot. 1994. Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation Antimicrob. Agents Chemother. 38:576-579.
5. Classen, D. C., J. P. Burke, C. D. Ford, S. Evershed, M. R. Aloia, J. K. Wilfahrt, and J. A. Elliott. 1990. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am. J. Med. 89:441-446.
6. de Azavedo, J. C., L. Trpeski, S. Pong-Porter, S. Matsumura, and D. E. Low. 1999. In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada. Antimicrob. Agents Chemother. 43:2299-2301.
7. Diekema, D. J., M. L. Beach, M. A. Pfaller, R. N. Jones, and SENTRY Participants Group. 2001. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin. Microbiol. Infect. 7:152-157.
8. Doern, G. V., M. J. Ferraro, A. B. Brueggemann, and K. L. Ruoff. 1996. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 40:891-894.
9. Donnelly, J. P., E. C. Dompeling, J. F. Meis, and B. E. de Pauw. 1995. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. Clin. Infect. Dis. 20:469-470.
10. Elting, L. S., G. P. Bodey, and B. H. Keefe. 1992. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin. Infect. Dis. 14:1201-1207.
11. Facklam, R. 2002. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin. Microbiol. Rev. 15:613-630.
12. Gershon, A. S., J. C. de Azavedo, A. McGeer, K. I. Ostrowska, D. Church, D. J. Hoban, G. K. Harding, K. Weiss, L. Abbott, F. Smaill, M. Gourdeau, G. Murray, D. E. Low, and Canadian Bacterial Surveillance. 2002. Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000. Antimicrob. Agents Chemother. 46:1553-1556.
13. Gordon, K. A., M. L. Beach, D. J. Biedenbach, R. N. Jones, P. R. Rhomberg, and A. H. Mutnick. 2002. Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. 43:157-162.
14. Haahr, V., N. A. Peterslund, and J. K. Moller. 1997. The influence of antimicrobial prophylaxis on the microbial and clinical findings in patients after autologous bone marrow transplantation. Scand. J. Infect. Dis. 29:623-626.
15. Hall, G. E., and L. M. Baddour. 2002. Apparent failure of endocarditis prophylaxis caused by penicillin-resistant Streptococcus mitis. Am. J. Med. Sci. 324:51-53.
16. Levitz, R. E. 1999. Prosthetic-valve endocarditis caused by penicillin-resistant Streptococcus mitis. N. Engl. J. Med. 340:1843-1844.
17. Levy, C. S., P. Kogulan, V. J. Gill, M. B. Croxton, J. G. Kane, and D. R. Lucey. 2001. Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin. Infect. Dis. 33:577-579.
18. Lonks, J. R., B. P. Dickinson, and V. Runarsdottir. 1999. Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and cefotaxime. N. Engl. J. Med. 341:1239.
19. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 6th ed. M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility testing; 12th informational supplement. MS100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Persson, L., T. Vikerfors, L. Sjoberg, P. Engervall, and U. Tidefelt. 2000. Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia. Scand. J. Infect. Dis. 32:615-621.
22. Pfaller, M. A., R. N. Jones, S. A. Marshall, M. B. Edmond, and R. P. Wenzel. 1997. Nosocomial streptococcal blood stream infections in the SCOPE program: species occurrence and antimicrobial resistance. Diagn. Microbiol. Infect. Dis. 29:259-263.
23. Piper, K. E., M. S. Rouse, K. L. Ronningen, J. M. Steckelberg, W. R. Wilson, and R. Patel. 2000. Trovafloxacin treatment of viridans group streptococcus experimental endocarditis. Antimicrob. Agents Chemother. 44:2554-2556.
24. Razonable, R. R., M. R. Litzow, Y. Khaliq, K. E. Piper, M. S. Rouse, and R. Patel. 2002. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin. Infect. Dis. 34:1469-1474.
25. Rolston, K. V., L. S. Elting, and G. P. Bodey. 1995. Bacteremia due to viridans streptococci in neutropenic patients. Am. J. Med. 99:450.
26. Sabella, C., D. Murphy, and J. Drummond-Webb. 2001. Endocarditis due to Streptococcus mitis with high-level resistance to penicillin and ceftriaxone. JAMA 285:2195.
27. Spanik, S., J. Trupl, A. Kunova, R. Botek, D. Sorkovska, E. Grey, M. Studena, J. Lacka, E. Oravcova, A. Krchnakova, V. Rusnakova, J. Svec, I. Krupova, S. Grausova, K. Stopkova, P. Keren, and V. Krcmery, Jr. 1997. Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis. Scand. J. Infect. Dis. 29:245-249.
28. Teng, L. J., P. R. Hsueh, Y. C. Chen, S. W. Ho, and K. T. Luh. 1998. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J. Antimicrob. Chemother. 41:621-627.